ClinicalTrials.gg

Program

Nitroglycerin

Also written as “Glyceryl Trinitrate”, “MED2005” and “IMX-150”.

Its studies are mostly in Raynaud Disease · Erectile Dysfunction · Coronary Artery Disease · Fissure in Ano · Connective Tissue Diseases, led by 5 companies.

Furthest: phase 4, since Dec 18, 200712 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediQuest Therapeutics40 open or runningphase 3since Dec 18, 2007May 29, 2007none ahead
Futura Medical Developments30 open or runningphase 3since Jan 15, 2019Jun 29, 2015none ahead
AbbVie20 open or runningphase 4since Aug 7, 2013Aug 28, 2007none ahead
Procris Pharmaceuticals20 open or runningphase 2since Mar 17, 2008Mar 17, 2008none ahead
Covis Pharma S.à.r.l.10 open or runningphase 2since Feb 18, 2016Feb 18, 2016none ahead

Also a collaborator on its studies: Merck and richmond-pharmacology-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2007First study: phase 2 study in Raynaud DiseaseNew to MediQuest TherapeuticsMediQuest Therapeutics · NCT00480753 · 15 enrolled · United States
  2. Aug 7, 2007Phase 1 study in HealthyMediQuest Therapeutics · NCT00513994 · 6 enrolled · United States
  3. Aug 28, 2007AbbVie's first study: phase 3 study in Fissure in AnoNew to AbbVieAbbVie · NCT00522041 · 248 enrolled
  4. Dec 18, 2007Phase 3 study in Raynaud DiseaseMediQuest Therapeutics · NCT00577304 · 200 enrolled · United States
  5. Mar 17, 2008Procris Pharmaceuticals's first study: phase 2 study in Diabetic Peripheral NeuropathyNew to Procris PharmaceuticalsProcris Pharmaceuticals · NCT00641953 · 155 enrolled · United States
  6. Jun 13, 2008Phase 1 study in Raynaud DiseaseProcris Pharmaceuticals · NCT00700518 · 10 enrolled · United States
  7. Feb 9, 2009Phase 1 study in Raynaud DiseaseMediQuest Therapeutics · NCT00841594 · 12 enrolled · United States
  8. Aug 7, 2013Phase 4 study in Fissure in AnoAbbVie · NCT01920074 · United States
  9. Jun 29, 2015Futura Medical Developments's first study: phase 2 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT02495467 · 232 enrolled · United Kingdom
  10. Feb 18, 2016Covis Pharma S.à.r.l.'s first study: phase 2 study in Raynaud's Phenomenon Secondary to Connective Tissue DiseaseNew to Covis Pharma S.à.r.l.Covis Pharma S.à.r.l. · NCT02688270 · 65 enrolled · United States
  11. Jan 24, 2018Phase 1 study in Erectile DysfunctionFutura Medical Developments · NCT04008732 · 40 enrolled · United Kingdom
  12. Jan 15, 2019Phase 3 study in Erectile DysfunctionFutura Medical Developments · NCT03813992 · 1,005 enrolled · Bulgaria, Czechia, Georgia and more

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ataciguatruleSanofiphase 33
praliciguatruleIronwood Pharmaceuticalsphase 28

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03813992Erectile Dysfunction · Bulgaria, Czechia, Georgia and more3CompletedFutura Medical DevelopmentsJul 21, 20191,005
NCT04008732Erectile Dysfunction · United Kingdom1CompletedFutura Medical DevelopmentsApr 16, 201840
NCT02688270Raynaud's Phenomenon Secondary to Connective Tissue Disease · United States2CompletedCovis Pharma S.à.r.l.Dec 201665
NCT02495467Erectile Dysfunction · United Kingdom2CompletedFutura Medical DevelopmentsJul 30, 2016232
NCT01920074Fissure in Ano · United States4WithdrawnAbbVieMar 20150
NCT00841594Raynaud Disease · United States1CompletedMediQuest TherapeuticsFeb 200912
NCT00700518Raynaud Disease · United States1CompletedProcris PharmaceuticalsNov 200810
NCT00641953Diabetic Peripheral Neuropathy · United States2CompletedProcris PharmaceuticalsMar 2008155
NCT00577304Raynaud Disease · United States3UNKNOWNMediQuest TherapeuticsMar 2008200
NCT00522041Fissure in Ano3CompletedAbbVieJul 2008248
NCT00513994Healthy · United States1CompletedMediQuest Therapeutics6
NCT00480753Raynaud Disease · United States2CompletedMediQuest Therapeutics15

How it is read

Names in the registry

  • “Nitroglycerin”, 4 entries
  • “Glyceryl Trinitrate”, 4 entries
  • “MED2005”, 2 entries
  • “IMX-150”, 2 entries
  • “Nitroglycerin spray”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.